Kara Kuhlman
Family Medicine · Colby, KSNPI 1558652818
Payments from drug & device makers
Across 100 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$339
- Amgen$327
- Novartis$121
- AstraZeneca$98
- Dexcom, Inc.$84
- Lilly USA, LLC$77
- plus $518 from 18 others
What the payments were for
- Food & beverage$1,563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $339 |
| Amgen | 22 | $327 |
| Novartis | 7 | $121 |
| AstraZeneca | 7 | $98 |
| Dexcom, Inc. | 4 | $84 |
| Lilly USA, LLC | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 1 | $74 |
| Novo Nordisk | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Grifols USA, LLC | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Pfizer | 2 | $29 |
| GE HealthCare | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| GSK | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Abbott | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,563 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BafiertamMonomethyl Fumarate | 11 | $71,857 |
| EliquisApixaban | 60 | $57,739 |
| TrulicityDulaglutide | 54 | $48,869 |
| JardianceEmpagliflozin | 33 | $25,956 |
| XareltoRivaroxaban | 27 | $21,729 |
| InvokametCanagliflozin/Metformin Hcl | 12 | $6,755 |
| MyrbetriqMirabegron | 27 | $5,461 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $4,523 |
| NovologInsulin Aspart | 22 | $4,359 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 12 | $2,603 |
| Potassium Chloride | 81 | $1,379 |
| Atorvastatin Calcium | 179 | $1,303 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,300 |
| Duloxetine Hcl | 42 | $1,257 |
| Fentanyl | 23 | $1,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Dilantin | $29 | $58,86174 claims |
| Lilly USA, LLCTrulicity | $77 | $48,86954 claims |
| Johnson & JohnsonXarelto, Invokamet | $12 | $28,48439 claims |
| Boehringer IngelheimJardiance | $15 | $25,95633 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $5,46127 claims |
| Novo NordiskNovolog | $57 | $4,35922 claims |
| GSKShingrix | $15 | $2,60312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Colby
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.